The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Oncogene Inhibitors Market Research Report 2024
Synopsis
The global Oncogene Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Oncogene Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Oncogene Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Oncogene Inhibitors include AstraZeneca, Merck Sharp & Dohme, Pfizer, Celgene, Novartis, Pacira BioSciences, Johnson & Johnson, Fresenius Kabi, Assertio, Takeda Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oncogene Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncogene Inhibitors.
The Oncogene Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Oncogene Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncogene Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
AstraZeneca
Merck Sharp & Dohme
Pfizer
Celgene
Novartis
Pacira BioSciences
Johnson & Johnson
Fresenius Kabi
Assertio
Takeda Pharmaceutical
Teva Pharmaceutical Industries
Cipla
Sun Pharmaceutical Industries
Shanghai Fosun Pharmaceutical
Ingenus
Segment by Type
Oral
Injection
Segment by Application
Cancer Treatment
Clinical Research
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oncogene Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oncogene Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Oncogene Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Oncogene Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Oncogene Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Oncogene Inhibitors include AstraZeneca, Merck Sharp & Dohme, Pfizer, Celgene, Novartis, Pacira BioSciences, Johnson & Johnson, Fresenius Kabi, Assertio, Takeda Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oncogene Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncogene Inhibitors.
The Oncogene Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Oncogene Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncogene Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
AstraZeneca
Merck Sharp & Dohme
Pfizer
Celgene
Novartis
Pacira BioSciences
Johnson & Johnson
Fresenius Kabi
Assertio
Takeda Pharmaceutical
Teva Pharmaceutical Industries
Cipla
Sun Pharmaceutical Industries
Shanghai Fosun Pharmaceutical
Ingenus
Segment by Type
Oral
Injection
Segment by Application
Cancer Treatment
Clinical Research
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oncogene Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oncogene Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Oncogene Inhibitors Market Overview
1.1 Product Definition
1.2 Oncogene Inhibitors by Type
1.2.1 Global Oncogene Inhibitors Market Value Comparison by Type (2024-2030)
1.2.2 Oral
1.2.3 Injection
1.3 Oncogene Inhibitors by Application
1.3.1 Global Oncogene Inhibitors Market Value by Application (2024-2030)
1.3.2 Cancer Treatment
1.3.3 Clinical Research
1.3.4 Other
1.4 Global Oncogene Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Oncogene Inhibitors Revenue 2019-2030
1.4.2 Global Oncogene Inhibitors Sales 2019-2030
1.4.3 Global Oncogene Inhibitors Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Oncogene Inhibitors Market Competition by Manufacturers
2.1 Global Oncogene Inhibitors Sales Market Share by Manufacturers (2019-2024)
2.2 Global Oncogene Inhibitors Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Oncogene Inhibitors Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Oncogene Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Oncogene Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oncogene Inhibitors, Product Type & Application
2.7 Global Key Manufacturers of Oncogene Inhibitors, Date of Enter into This Industry
2.8 Global Oncogene Inhibitors Market Competitive Situation and Trends
2.8.1 Global Oncogene Inhibitors Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Oncogene Inhibitors Players Market Share by Revenue
2.8.3 Global Oncogene Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Oncogene Inhibitors Market Scenario by Region
3.1 Global Oncogene Inhibitors Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Oncogene Inhibitors Sales by Region: 2019-2030
3.2.1 Global Oncogene Inhibitors Sales by Region: 2019-2024
3.2.2 Global Oncogene Inhibitors Sales by Region: 2025-2030
3.3 Global Oncogene Inhibitors Revenue by Region: 2019-2030
3.3.1 Global Oncogene Inhibitors Revenue by Region: 2019-2024
3.3.2 Global Oncogene Inhibitors Revenue by Region: 2025-2030
3.4 North America Oncogene Inhibitors Market Facts & Figures by Country
3.4.1 North America Oncogene Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Oncogene Inhibitors Sales by Country (2019-2030)
3.4.3 North America Oncogene Inhibitors Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oncogene Inhibitors Market Facts & Figures by Country
3.5.1 Europe Oncogene Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Oncogene Inhibitors Sales by Country (2019-2030)
3.5.3 Europe Oncogene Inhibitors Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oncogene Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific Oncogene Inhibitors Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Oncogene Inhibitors Sales by Region (2019-2030)
3.6.3 Asia Pacific Oncogene Inhibitors Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Oncogene Inhibitors Market Facts & Figures by Country
3.7.1 Latin America Oncogene Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Oncogene Inhibitors Sales by Country (2019-2030)
3.7.3 Latin America Oncogene Inhibitors Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Oncogene Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa Oncogene Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Oncogene Inhibitors Sales by Country (2019-2030)
3.8.3 Middle East and Africa Oncogene Inhibitors Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oncogene Inhibitors Sales by Type (2019-2030)
4.1.1 Global Oncogene Inhibitors Sales by Type (2019-2024)
4.1.2 Global Oncogene Inhibitors Sales by Type (2025-2030)
4.1.3 Global Oncogene Inhibitors Sales Market Share by Type (2019-2030)
4.2 Global Oncogene Inhibitors Revenue by Type (2019-2030)
4.2.1 Global Oncogene Inhibitors Revenue by Type (2019-2024)
4.2.2 Global Oncogene Inhibitors Revenue by Type (2025-2030)
4.2.3 Global Oncogene Inhibitors Revenue Market Share by Type (2019-2030)
4.3 Global Oncogene Inhibitors Price by Type (2019-2030)
5 Segment by Application
5.1 Global Oncogene Inhibitors Sales by Application (2019-2030)
5.1.1 Global Oncogene Inhibitors Sales by Application (2019-2024)
5.1.2 Global Oncogene Inhibitors Sales by Application (2025-2030)
5.1.3 Global Oncogene Inhibitors Sales Market Share by Application (2019-2030)
5.2 Global Oncogene Inhibitors Revenue by Application (2019-2030)
5.2.1 Global Oncogene Inhibitors Revenue by Application (2019-2024)
5.2.2 Global Oncogene Inhibitors Revenue by Application (2025-2030)
5.2.3 Global Oncogene Inhibitors Revenue Market Share by Application (2019-2030)
5.3 Global Oncogene Inhibitors Price by Application (2019-2030)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Company Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Oncogene Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.1.4 AstraZeneca Oncogene Inhibitors Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Merck Sharp & Dohme
6.2.1 Merck Sharp & Dohme Company Information
6.2.2 Merck Sharp & Dohme Description and Business Overview
6.2.3 Merck Sharp & Dohme Oncogene Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck Sharp & Dohme Oncogene Inhibitors Product Portfolio
6.2.5 Merck Sharp & Dohme Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Company Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Oncogene Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Pfizer Oncogene Inhibitors Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Celgene
6.4.1 Celgene Company Information
6.4.2 Celgene Description and Business Overview
6.4.3 Celgene Oncogene Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Celgene Oncogene Inhibitors Product Portfolio
6.4.5 Celgene Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Company Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Oncogene Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Novartis Oncogene Inhibitors Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Pacira BioSciences
6.6.1 Pacira BioSciences Company Information
6.6.2 Pacira BioSciences Description and Business Overview
6.6.3 Pacira BioSciences Oncogene Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Pacira BioSciences Oncogene Inhibitors Product Portfolio
6.6.5 Pacira BioSciences Recent Developments/Updates
6.7 Johnson & Johnson
6.7.1 Johnson & Johnson Company Information
6.7.2 Johnson & Johnson Description and Business Overview
6.7.3 Johnson & Johnson Oncogene Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Johnson & Johnson Oncogene Inhibitors Product Portfolio
6.7.5 Johnson & Johnson Recent Developments/Updates
6.8 Fresenius Kabi
6.8.1 Fresenius Kabi Company Information
6.8.2 Fresenius Kabi Description and Business Overview
6.8.3 Fresenius Kabi Oncogene Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Fresenius Kabi Oncogene Inhibitors Product Portfolio
6.8.5 Fresenius Kabi Recent Developments/Updates
6.9 Assertio
6.9.1 Assertio Company Information
6.9.2 Assertio Description and Business Overview
6.9.3 Assertio Oncogene Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Assertio Oncogene Inhibitors Product Portfolio
6.9.5 Assertio Recent Developments/Updates
6.10 Takeda Pharmaceutical
6.10.1 Takeda Pharmaceutical Company Information
6.10.2 Takeda Pharmaceutical Description and Business Overview
6.10.3 Takeda Pharmaceutical Oncogene Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Takeda Pharmaceutical Oncogene Inhibitors Product Portfolio
6.10.5 Takeda Pharmaceutical Recent Developments/Updates
6.11 Teva Pharmaceutical Industries
6.11.1 Teva Pharmaceutical Industries Company Information
6.11.2 Teva Pharmaceutical Industries Description and Business Overview
6.11.3 Teva Pharmaceutical Industries Oncogene Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Teva Pharmaceutical Industries Oncogene Inhibitors Product Portfolio
6.11.5 Teva Pharmaceutical Industries Recent Developments/Updates
6.12 Cipla
6.12.1 Cipla Company Information
6.12.2 Cipla Description and Business Overview
6.12.3 Cipla Oncogene Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Cipla Oncogene Inhibitors Product Portfolio
6.12.5 Cipla Recent Developments/Updates
6.13 Sun Pharmaceutical Industries
6.13.1 Sun Pharmaceutical Industries Company Information
6.13.2 Sun Pharmaceutical Industries Description and Business Overview
6.13.3 Sun Pharmaceutical Industries Oncogene Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Sun Pharmaceutical Industries Oncogene Inhibitors Product Portfolio
6.13.5 Sun Pharmaceutical Industries Recent Developments/Updates
6.14 Shanghai Fosun Pharmaceutical
6.14.1 Shanghai Fosun Pharmaceutical Company Information
6.14.2 Shanghai Fosun Pharmaceutical Description and Business Overview
6.14.3 Shanghai Fosun Pharmaceutical Oncogene Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Shanghai Fosun Pharmaceutical Oncogene Inhibitors Product Portfolio
6.14.5 Shanghai Fosun Pharmaceutical Recent Developments/Updates
6.15 Ingenus
6.15.1 Ingenus Company Information
6.15.2 Ingenus Description and Business Overview
6.15.3 Ingenus Oncogene Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Ingenus Oncogene Inhibitors Product Portfolio
6.15.5 Ingenus Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oncogene Inhibitors Industry Chain Analysis
7.2 Oncogene Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oncogene Inhibitors Production Mode & Process
7.4 Oncogene Inhibitors Sales and Marketing
7.4.1 Oncogene Inhibitors Sales Channels
7.4.2 Oncogene Inhibitors Distributors
7.5 Oncogene Inhibitors Customers
8 Oncogene Inhibitors Market Dynamics
8.1 Oncogene Inhibitors Industry Trends
8.2 Oncogene Inhibitors Market Drivers
8.3 Oncogene Inhibitors Market Challenges
8.4 Oncogene Inhibitors Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Oncogene Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Oncogene Inhibitors Market Value by Application (2024-2030) & (US$ Million)
Table 3. Global Oncogene Inhibitors Market Competitive Situation by Manufacturers in 2023
Table 4. Global Oncogene Inhibitors Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Oncogene Inhibitors Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Oncogene Inhibitors Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Oncogene Inhibitors Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Oncogene Inhibitors Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Oncogene Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Oncogene Inhibitors, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Oncogene Inhibitors, Product Type & Application
Table 12. Global Key Manufacturers of Oncogene Inhibitors, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Oncogene Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncogene Inhibitors as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Oncogene Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Oncogene Inhibitors Sales by Region (2019-2024) & (K Units)
Table 18. Global Oncogene Inhibitors Sales Market Share by Region (2019-2024)
Table 19. Global Oncogene Inhibitors Sales by Region (2025-2030) & (K Units)
Table 20. Global Oncogene Inhibitors Sales Market Share by Region (2025-2030)
Table 21. Global Oncogene Inhibitors Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Oncogene Inhibitors Revenue Market Share by Region (2019-2024)
Table 23. Global Oncogene Inhibitors Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Oncogene Inhibitors Revenue Market Share by Region (2025-2030)
Table 25. North America Oncogene Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Oncogene Inhibitors Sales by Country (2019-2024) & (K Units)
Table 27. North America Oncogene Inhibitors Sales by Country (2025-2030) & (K Units)
Table 28. North America Oncogene Inhibitors Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Oncogene Inhibitors Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Oncogene Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Oncogene Inhibitors Sales by Country (2019-2024) & (K Units)
Table 32. Europe Oncogene Inhibitors Sales by Country (2025-2030) & (K Units)
Table 33. Europe Oncogene Inhibitors Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Oncogene Inhibitors Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Oncogene Inhibitors Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Oncogene Inhibitors Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Oncogene Inhibitors Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Oncogene Inhibitors Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Oncogene Inhibitors Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Oncogene Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Oncogene Inhibitors Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Oncogene Inhibitors Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Oncogene Inhibitors Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Oncogene Inhibitors Revenue Market Share by Country (2019-2024)
Table 45. Middle East and Africa Oncogene Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East and Africa Oncogene Inhibitors Sales by Country (2019-2024) & (K Units)
Table 47. Middle East and Africa Oncogene Inhibitors Sales by Country (2025-2030) & (K Units)
Table 48. Middle East and Africa Oncogene Inhibitors Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East and Africa Oncogene Inhibitors Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Oncogene Inhibitors Sales (K Units) by Type (2019-2024)
Table 51. Global Oncogene Inhibitors Sales (K Units) by Type (2025-2030)
Table 52. Global Oncogene Inhibitors Sales Market Share by Type (2019-2024)
Table 53. Global Oncogene Inhibitors Sales Market Share by Type (2025-2030)
Table 54. Global Oncogene Inhibitors Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Oncogene Inhibitors Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Oncogene Inhibitors Revenue Market Share by Type (2019-2024)
Table 57. Global Oncogene Inhibitors Revenue Market Share by Type (2025-2030)
Table 58. Global Oncogene Inhibitors Price (US$/Unit) by Type (2019-2024)
Table 59. Global Oncogene Inhibitors Price (US$/Unit) by Type (2025-2030)
Table 60. Global Oncogene Inhibitors Sales (K Units) by Application (2019-2024)
Table 61. Global Oncogene Inhibitors Sales (K Units) by Application (2025-2030)
Table 62. Global Oncogene Inhibitors Sales Market Share by Application (2019-2024)
Table 63. Global Oncogene Inhibitors Sales Market Share by Application (2025-2030)
Table 64. Global Oncogene Inhibitors Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Oncogene Inhibitors Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Oncogene Inhibitors Revenue Market Share by Application (2019-2024)
Table 67. Global Oncogene Inhibitors Revenue Market Share by Application (2025-2030)
Table 68. Global Oncogene Inhibitors Price (US$/Unit) by Application (2019-2024)
Table 69. Global Oncogene Inhibitors Price (US$/Unit) by Application (2025-2030)
Table 70. AstraZeneca Company Information
Table 71. AstraZeneca Description and Business Overview
Table 72. AstraZeneca Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. AstraZeneca Oncogene Inhibitors Product
Table 74. AstraZeneca Recent Developments/Updates
Table 75. Merck Sharp & Dohme Company Information
Table 76. Merck Sharp & Dohme Description and Business Overview
Table 77. Merck Sharp & Dohme Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Merck Sharp & Dohme Oncogene Inhibitors Product
Table 79. Merck Sharp & Dohme Recent Developments/Updates
Table 80. Pfizer Company Information
Table 81. Pfizer Description and Business Overview
Table 82. Pfizer Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Pfizer Oncogene Inhibitors Product
Table 84. Pfizer Recent Developments/Updates
Table 85. Celgene Company Information
Table 86. Celgene Description and Business Overview
Table 87. Celgene Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Celgene Oncogene Inhibitors Product
Table 89. Celgene Recent Developments/Updates
Table 90. Novartis Company Information
Table 91. Novartis Description and Business Overview
Table 92. Novartis Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Novartis Oncogene Inhibitors Product
Table 94. Novartis Recent Developments/Updates
Table 95. Pacira BioSciences Company Information
Table 96. Pacira BioSciences Description and Business Overview
Table 97. Pacira BioSciences Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Pacira BioSciences Oncogene Inhibitors Product
Table 99. Pacira BioSciences Recent Developments/Updates
Table 100. Johnson & Johnson Company Information
Table 101. Johnson & Johnson Description and Business Overview
Table 102. Johnson & Johnson Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Johnson & Johnson Oncogene Inhibitors Product
Table 104. Johnson & Johnson Recent Developments/Updates
Table 105. Fresenius Kabi Company Information
Table 106. Fresenius Kabi Description and Business Overview
Table 107. Fresenius Kabi Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Fresenius Kabi Oncogene Inhibitors Product
Table 109. Fresenius Kabi Recent Developments/Updates
Table 110. Assertio Company Information
Table 111. Assertio Description and Business Overview
Table 112. Assertio Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Assertio Oncogene Inhibitors Product
Table 114. Assertio Recent Developments/Updates
Table 115. Takeda Pharmaceutical Company Information
Table 116. Takeda Pharmaceutical Description and Business Overview
Table 117. Takeda Pharmaceutical Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Takeda Pharmaceutical Oncogene Inhibitors Product
Table 119. Takeda Pharmaceutical Recent Developments/Updates
Table 120. Teva Pharmaceutical Industries Company Information
Table 121. Teva Pharmaceutical Industries Description and Business Overview
Table 122. Teva Pharmaceutical Industries Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Teva Pharmaceutical Industries Oncogene Inhibitors Product
Table 124. Teva Pharmaceutical Industries Recent Developments/Updates
Table 125. Cipla Company Information
Table 126. Cipla Description and Business Overview
Table 127. Cipla Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Cipla Oncogene Inhibitors Product
Table 129. Cipla Recent Developments/Updates
Table 130. Sun Pharmaceutical Industries Company Information
Table 131. Sun Pharmaceutical Industries Description and Business Overview
Table 132. Sun Pharmaceutical Industries Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. Sun Pharmaceutical Industries Oncogene Inhibitors Product
Table 134. Sun Pharmaceutical Industries Recent Developments/Updates
Table 135. Shanghai Fosun Pharmaceutical Company Information
Table 136. Shanghai Fosun Pharmaceutical Description and Business Overview
Table 137. Shanghai Fosun Pharmaceutical Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. Shanghai Fosun Pharmaceutical Oncogene Inhibitors Product
Table 139. Shanghai Fosun Pharmaceutical Recent Developments/Updates
Table 140. Ingenus Company Information
Table 141. Ingenus Description and Business Overview
Table 142. Ingenus Oncogene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. Ingenus Oncogene Inhibitors Product
Table 144. Ingenus Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Oncogene Inhibitors Distributors List
Table 148. Oncogene Inhibitors Customers List
Table 149. Oncogene Inhibitors Market Trends
Table 150. Oncogene Inhibitors Market Drivers
Table 151. Oncogene Inhibitors Market Challenges
Table 152. Oncogene Inhibitors Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
Table 156. Authors List of This Report
List of Figures
Figure 1. Product Picture of Oncogene Inhibitors
Figure 2. Global Oncogene Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Oncogene Inhibitors Market Share by Type: 2023 & 2030
Figure 4. Oral Product Picture
Figure 5. Injection Product Picture
Figure 6. Global Oncogene Inhibitors Market Value by Application (2024-2030) & (US$ Million)
Figure 7. Global Oncogene Inhibitors Market Share by Application: 2023 & 2030
Figure 8. Cancer Treatment
Figure 9. Clinical Research
Figure 10. Other
Figure 11. Global Oncogene Inhibitors Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Oncogene Inhibitors Market Size (2019-2030) & (US$ Million)
Figure 13. Global Oncogene Inhibitors Sales (2019-2030) & (K Units)
Figure 14. Global Oncogene Inhibitors Average Price (US$/Unit) & (2019-2030)
Figure 15. Oncogene Inhibitors Report Years Considered
Figure 16. Oncogene Inhibitors Sales Share by Manufacturers in 2023
Figure 17. Global Oncogene Inhibitors Revenue Share by Manufacturers in 2023
Figure 18. Global 5 and 10 Largest Oncogene Inhibitors Players: Market Share by Revenue in Oncogene Inhibitors in 2023
Figure 19. Oncogene Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 20. Global Oncogene Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Oncogene Inhibitors Sales Market Share by Country (2019-2030)
Figure 22. North America Oncogene Inhibitors Revenue Market Share by Country (2019-2030)
Figure 23. United States Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Oncogene Inhibitors Sales Market Share by Country (2019-2030)
Figure 26. Europe Oncogene Inhibitors Revenue Market Share by Country (2019-2030)
Figure 27. Germany Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Oncogene Inhibitors Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Oncogene Inhibitors Revenue Market Share by Region (2019-2030)
Figure 34. China Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. China Taiwan Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Southeast Asia Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Latin America Oncogene Inhibitors Sales Market Share by Country (2019-2030)
Figure 42. Mexico Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Brazil Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Argentina Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Colombia Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Middle East and Africa Oncogene Inhibitors Sales Market Share by Country (2019-2030)
Figure 47. Middle East and Africa Oncogene Inhibitors Revenue Market Share by Country (2019-2030)
Figure 48. Turkey Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. UAE Oncogene Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Global Sales Market Share of Oncogene Inhibitors by Type (2019-2030)
Figure 52. Global Revenue Market Share of Oncogene Inhibitors by Type (2019-2030)
Figure 53. Global Oncogene Inhibitors Price (US$/Unit) by Type (2019-2030)
Figure 54. Global Sales Market Share of Oncogene Inhibitors by Application (2019-2030)
Figure 55. Global Revenue Market Share of Oncogene Inhibitors by Application (2019-2030)
Figure 56. Global Oncogene Inhibitors Price (US$/Unit) by Application (2019-2030)
Figure 57. Oncogene Inhibitors Value Chain
Figure 58. Oncogene Inhibitors Production Process
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
